Direct to consumer advertising -- Mansfield et al. 330 (7481): 5 -- BMJ
This article deals with a new industry strategy, bypassing professionals, as they are progressively aware of the conflict of interest, and pressed by scientific societies and ethical committees to control manipulation of physicians.
FDA to review "missing" drug company documents -- Lenzer 330 (7481): 7 -- BMJ
Eli Lilly & Prozac affaire.
The additional question is not just scientific, but moral: is it right to hidden documents and lack of transparency for secondary interest?
No comments:
Post a Comment